Better Outcomes Through Improved Drug Delivery

About Endurx

EnduRx, a virtual, pre-clinical company, is developing a peptide-directed nanoparticle drug delivery platform and therapeutics for hard-to-treat solid tumors and selected other indications.

Drug delivery

EnduRx therapeutic candidates are polymeric nanoparticles designed to achieve tumor-specific delivery of active pharmaceutical ingredients (API’s) that internalize into cells throughout the tumor parenchyma while avoiding healthy tissue.

Published foundational studies by an accomplished institutional team showed significant tumor volume reduction and sometimes complete tumor elimination. EnduRx is building on these studies to develop nanoparticles with improved efficacy, safety and robustness.

Tumor-specific delivery of highly-toxic chemotherapy agents and other APIs would offer reduced systemic toxicity and thereby improve both drug efficacy and patient experience. Improved patient experience can increase compliance well as quality-of-life during treatment, potentially further improving outcomes.

Pipeline

ERXC101

Triple-negative breast cancer and other solid tumors

Currently funded by a DoD CDMRP Breast Cancer Program grant that EnduRx shares with an accomplished breast cancer team at MD Anderson Cancer Center in Houston, this program targets a ubiquitous mitochondrial protein that translocates to the surface of cells in the tumor microenvironment. Pre-clinical work is underway with IND-enabling work planned through 2023 and first-in-human dosing in 2024.

ERXC102

Ovarian cancer and
peritoneal carcinomatosis 

Anticipated non-dilutive funding will launch this program, a collaboration with a noted ovarian cancer team at MD Anderson Cancer Center, utilizing intraperitoneal administration to facilitate tumor-specific delivery of API’s optimized for this indication.

ERXC103

Glioblastoma and other brain tumors

Future funding will launch this program, building on foundational work by a distinguished researcher then at the Salk Institute, to develop a candidate able to cross the blood-brain barrier and reach and treat these tumor types. First-in-human Phase 0 trials at a leading brain tumor clinic are anticipated once the candidate molecule has shown efficacy in animal models.

ERXL201 

Reduction of atherosclerotic plaque

Anticipated funding will launch this program, building on published foundational research that demonstrated reduction of atherosclerotic plaque by targeting its macrophage component, a non-lipid approach that offers the possibility of a first-in-class treatment for this widespread condition.

ERXR3xx 

Collaborations to improve delivery of existing approved therapeutics


The EnduRx peptide-directed polymeric nanoparticle platform technology offers the potential to improve tumor-specific delivery of a range other approved therapeutics and developmental candidates. EnduRx seeks collaborations with other companies interested in application of our drug delivery platform to their molecule.

 

Our Team

David Bramhill, PhD

Director of Peptide Chemistry
David’s experience provides EnduRx with peptide-related medicinal chemistry knowledge enabling development and optimization of this element of the EnduRx drug delivery platform technology.
Mark Chapman

Mark Chapman PhD​

Director of Biology​
Dr. Mark Chapman is a veteran of large and small biotech companies. He is well versed in all aspects of drug discovery, including target selection, validation, screening, hit-to-lead, lead optimization, preclinical testing, candidate selection, and early clinical development. He has worked with small molecules as well as therapeutic antibodies.
Steve Morris

Steve Morris, MD​

Chief Medical Officer
Steve’s experience as a hospitalist and researcher with St Jude’s Children’s Research Hospital and subsequently with commercial projects in diagnostics and therapeutics equips him for leadership of EnduRx pre-clinical activities and for development of future clinical strategies.

David Loynd

President & CEO
David’s diverse business, financial and project experience, including several drug delivery projects, equips him to lead EnduRx’s virtual preclinical activities, the identification and integration of external resources, expansion of team capabilities, transition from the virtual business model, and development and execution of strategy including funding.
James MacKay

James Mackay

Founder and CEO,
Aristea Therapeutics,
Advisor​
James’ experience with a major pharmaceutical company and his broad understanding of the pharmaceutical industry and its components provides guidance to EnduRx management on operational and strategic matters.

Michael Howell

Chief Scientific Officer, Dermtech,
Advisor​
Michael’s experience with immune-oncology and traditional treatment modalities provides EnduRx with science-based guidance on partnership and market opportunities.

Contact Us

As a virtual pre-clinical company, EnduRx utilizes resources across the US in locations including Boston, Memphis, Houston, Tucson, Phoenix and Scottsdale, San Diego and elsewhere.  

Corporate Office: 
EnduRx Pharmaceuticals Inc.

8340 N Thornydale Rd Suite 110-328
Tucson, AZ 85741
phone: (855) 368-2878
(be prepared to leave a voicemail)

Please do not mail unsolicited materials to our Corporate Office address.

Contact should be initiated by email to
David Loynd, President & CEO:
dloynd at endurxpharm dot com

We welcome communication with the potential to add value but persistent unwanted solicitation and spam will be blocked.